SCHEMBL30748944

SCHEMBL30748944

O=C1N(c2ccc(N3CCOCC3)cc2)c2nc(Cl)ncc2C12CCOCC2

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNE1 P24864 1/20 0.39
CDK2 P24941 1/20 0.39
MAPT P10636 5/20 0.38
RAD51 Q06609 2/20 0.38
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
POLB P06746 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
AKR1C3 P42330 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.35
TRPV1 Q8NER1 1/20 0.35
ALDH1A1 P00352 1/20 0.34
SLC6A2 P23975 1/20 0.34
SLC6A4 P31645 1/20 0.34
SLC6A3 Q01959 1/20 0.34
TNKS O95271 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2C9 P11712 1/20 0.34
TNKS2 Q9H2K2 1/20 0.34
LRRK2 Q5S007 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30748964 0.84 CCNE1 (0.37) CCNE1CDK2MAPTMEN1KMT2A
SCHEMBL30748777 0.81 PRKDC (0.39) MAPTRAD51POLBALDH1A1
SCHEMBL30748888 0.80 CCNE1 (0.39) CCNE1CDK2MAPTMEN1KMT2A
SCHEMBL30749021 0.78 CCNE1 (0.36) CCNE1CDK2MEN1KMT2APOLB
SCHEMBL30749086 0.77 CCNE1 (0.35) CCNE1CDK2MEN1KMT2ALRRK2
SCHEMBL30749140 0.76 MAPT (0.39) MAPTRAD51MEN1KMT2AL3MBTL1
SCHEMBL30748809 0.75 CCNE1 (0.45) CCNE1CDK2MAPTALDH1A1
SCHEMBL30748962 0.70 LIPE (0.38) CCNE1CDK2ALDH1A1
SCHEMBL30748803 0.70 CCNE1 (0.39) CCNE1CDK2
SCHEMBL31691222 0.70 CCNE1 (0.40) CCNE1CDK2MAPTSMN1; SMN2TRPV1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2025-10-02 US disclosed
EP-4565588-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF Suzhou Keen Therapeutics Co., Ltd. (CN) 2025-06-11 EP disclosed
WO-2023241620-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2023-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF VHL, BRCA1, TERT CCNE1 2310/4885CDK2 680/4885MAPT 3029/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.